Reported about 15 hours ago
This article explores a bullish thesis on Harrow, Inc. (HROW), a U.S. ophthalmology pharmaceutical company expanding its portfolio with successful products like VEVYE and upcoming launches like BYQLOVI. Financially, Harrow reported a 30% year-over-year revenue increase, with ambitious goals to reach $280 million in 2025 and potentially building a market cap over $6 billion by 2028. However, risks such as significant debt and reimbursement pressures remain, with the stock down about 13% since September 2024.
Source: YAHOO